Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01851642
Other study ID # IRB201501051
Secondary ID 69908-2007
Status Recruiting
Phase
First received
Last updated
Start date August 9, 2007
Est. completion date July 20, 2033

Study information

Verified date August 2023
Source University of Florida
Contact Jesse R West, RN, CCRC
Phone 352-273-8666
Email jesse.west@medicine.ufl.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to look at how Alpha-1-antitrypsin (AAT) deficiency and Cystic Fibrosis (CF) affect white blood cells in the lungs, called macrophages, and their ability to work.


Description:

AAT deficiency is a genetic disorder that affects around 100,000 people in the USA, including 1-3% of all people diagnosed with chronic obstructive pulmonary disease (COPD). In AAT deficient people diagnosed with COPD, it was originally believed the cause of the disease was due to a lack of supply of alpha-1 antitrypsin. However, early information gathered in our laboratory suggests another cause of the development of COPD and the progressing of the disease may be due to a malfunction in macrophages. CF is also a genetic disorder which affects 1/300 births among the Caucasian population. One of the main symptoms of CF is inflammation of the lung tissue. Lung macrophages play a major role in lung inflammation as well as in helping to resolve the inflammation. Inflammation is an important defense of the body. It is the body's response to infection causing germs and things that may cause irritation, as well as, a way for the body to repair damaged tissue. We suggest that the effects of AAT deficiency and CF decreases the inflammation response in the lungs and also restricts the ability of macrophages to correct that inflammation once it occurs.


Recruitment information / eligibility

Status Recruiting
Enrollment 220
Est. completion date July 20, 2033
Est. primary completion date July 20, 2032
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Signed informed consent - Male or female 18 years of age or older - Negative pregnancy test for women of childbearing potential - Hemoglobin >12.5 g/dl measured on the day of participation - Negative urine nicotine test Exclusion Criteria: - Pregnancy or breastfeeding - Weight < 50 kg - History of anemia requiring blood transfusions, erythropoietin supplementation, or iron supplementation within the past 36 months - Known hemoglobin <12.5 g/dl within the past 90 days - Systolic blood pressure > 180 mmHg and/or diastolic blood pressure >100 mmHg - Poor venous access - Large volume blood donation (>200 ml or 7 ounces) within the previous 56 days (e.g. blood donation for the purposes of blood banking) - Clinically significant cardiac, hemostatic or neurological impairment or any other significant medical condition that, in the opinion of the investigator would affect subject safety (e.g., recent myocardial infarction, history of prolonged bleeding time, cerebral vascular accident, advanced cancer or uncontrolled medical condition) - Psychiatric or cognitive disturbance or illness that would affect subject safety - Current smoker

Study Design


Intervention

Procedure:
History and physical exam.
At every study visit, participant's will be asked about their medical history and will have a physical exam.
Blood draw.
At each study visit, participants will have an intravenous catheter (IV) placed in one of their veins and blood will be drawn from the IV for study testing.
Pulmonary function testing.
At every study visit, participants will have their lung function assessed. This is done by blowing forcefully at least 3 times into a tube. Testing will be done two times; before and after the use of an Albuterol inhaler.
Drug:
Albuterol inhaler.
At every study visit, participating subjects will take 2 puffs of an Albuterol inhaler after the first set of PFTs, but before the second set of PFTs. There will be at least a 30 minute period after the use of the Albuterol inhaler and the second set of PFTs.

Locations

Country Name City State
United States Shands at the University of Florida Gainesville Florida

Sponsors (1)

Lead Sponsor Collaborator
University of Florida

Country where clinical trial is conducted

United States, 

References & Publications (10)

Blank CA, Brantly M. Clinical features and molecular characteristics of alpha 1-antitrypsin deficiency. Ann Allergy. 1994 Feb;72(2):105-20; quiz 120-2. Erratum In: Ann Allergy 1994 Apr;72(4):305. — View Citation

Hidvegi T, Schmidt BZ, Hale P, Perlmutter DH. Accumulation of mutant alpha1-antitrypsin Z in the endoplasmic reticulum activates caspases-4 and -12, NFkappaB, and BAP31 but not the unfolded protein response. J Biol Chem. 2005 Nov 25;280(47):39002-15. doi: 10.1074/jbc.M508652200. Epub 2005 Sep 23. — View Citation

Jeppsson JO. Amino acid substitution Glu leads to Lys alpha1-antitrypsin PiZ. FEBS Lett. 1976 Jun 1;65(2):195-7. doi: 10.1016/0014-5793(76)80478-4. No abstract available. — View Citation

Kaufman RJ. Orchestrating the unfolded protein response in health and disease. J Clin Invest. 2002 Nov;110(10):1389-98. doi: 10.1172/JCI16886. No abstract available. — View Citation

Lomas DA, Evans DL, Finch JT, Carrell RW. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature. 1992 Jun 18;357(6379):605-7. doi: 10.1038/357605a0. — View Citation

Newman BH. Donor reactions and injuries from whole blood donation. Transfus Med Rev. 1997 Jan;11(1):64-75. doi: 10.1016/s0887-7963(97)80011-9. — View Citation

Oda Y, Okada T, Yoshida H, Kaufman RJ, Nagata K, Mori K. Derlin-2 and Derlin-3 are regulated by the mammalian unfolded protein response and are required for ER-associated degradation. J Cell Biol. 2006 Jan 30;172(3):383-93. doi: 10.1083/jcb.200507057. — View Citation

Perlmutter DH. Liver injury in alpha1-antitrypsin deficiency: an aggregated protein induces mitochondrial injury. J Clin Invest. 2002 Dec;110(11):1579-83. doi: 10.1172/JCI16787. No abstract available. — View Citation

Seager Danciger J, Lutz M, Hama S, Cruz D, Castrillo A, Lazaro J, Phillips R, Premack B, Berliner J. Method for large scale isolation, culture and cryopreservation of human monocytes suitable for chemotaxis, cellular adhesion assays, macrophage and dendritic cell differentiation. J Immunol Methods. 2004 May;288(1-2):123-34. doi: 10.1016/j.jim.2004.03.003. — View Citation

Yoshida A, Lieberman J, Gaidulis L, Ewing C. Molecular abnormality of human alpha1-antitrypsin variant (Pi-ZZ) associated with plasma activity deficiency. Proc Natl Acad Sci U S A. 1976 Apr;73(4):1324-8. doi: 10.1073/pnas.73.4.1324. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of macrophage function. From every study participant, we will collect blood from a vein through the placement of an intravenous catheter (IV). We will complete various experiments that will allow us to see how well each participant's macrophage cells are working. On average, within 30 days from the time the blood is collected.
Secondary Comparison of the amount of alpha-1 antitrypsin in the blood. From every study participant, we will collect blood from a vein through an IV. On average, within 30 days from the time the blood was collected.
Secondary Comparison of the amount of an inflammatory marker in the blood, called C-reactive protein. From every study participant, we will collect blood from a vein through and IV. On average, within 30 days from the time the blood is collected.
Secondary Evaluation of lung function. Lung function testing will be done on every study participant. This is is done by forcefully blowing into a tube on at least 3 separate occasions. Albuterol, an inhaled medication used to expand lung airways, will be given after lung function testing and then the testing will be repeated after 30 minutes. On average, within 30 days from the time the testing is completed.
See also
  Status Clinical Trial Phase
Completed NCT02547532 - Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency
Completed NCT01615484 - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability N/A
Completed NCT00005292 - Alpha1-antitrypsin Deficiency Registry N/A
Withdrawn NCT02900183 - Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels Phase 2
Terminated NCT02502201 - Environment Effect on Six-Minute Walk Test Performance N/A
Completed NCT01810458 - Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)
Active, not recruiting NCT04262284 - Respreeza® Self-administration and Learning Program (AmAREtTI Study)
Recruiting NCT06186492 - A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1) Phase 1
Recruiting NCT06405633 - A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD Phase 1/Phase 2
Completed NCT01054339 - Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency Phase 2
Completed NCT03815396 - Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency Phase 1
Completed NCT03008915 - Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency Phase 2
Completed NCT01419158 - Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD) N/A
Recruiting NCT00500123 - The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
Completed NCT05727800 - A Phase 1, First-in-human Study of VX-668 Phase 1
Active, not recruiting NCT05643495 - A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype Phase 2
Terminated NCT02363946 - A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD) Phase 1
Completed NCT02810327 - Alpha-1 Carrier Genomics Study
Completed NCT03804021 - Long-Term Follow-up Study of ADVM-043
Active, not recruiting NCT02014415 - Alpha-1 Antitrypsin Deficiency Adult Liver Study